<DOC>
	<DOC>NCT00800787</DOC>
	<brief_summary>A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.</brief_summary>
	<brief_title>Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation</brief_title>
	<detailed_description>This is a phase 3 prospective, single arm open label study to be conducted t approximately 4 study sited located in th e USA. Approximately 25 HBV DNA negative patients who underwent liver transplant at least one year prior, due to chronic hepatitis B infection will bwe eligible for study participation. The study consist of a total of 16 study visit and the duration of participation will be 20 weeks for each patients. Patients will be converted from the intravenous standard HBIG to Nabi-HB subcutaneous administration according to the individual scheduled dosing interval.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<criteria>Male or female patients 18 years old or older as of visit one. If female is not trying to conserve, not lactating, and has a negative serum pregnancy test and use an acceptable method of contraception or be at least one year postmenopausal or surgically sterile. Able to provide written informed consent. First time liver transplant recipient. Primary, single organ recipient (deceased donor &lt;65 years old). receive regular longterm HBIG prophylaxis with stabilized HBIG dosage and administration intervals. Have negative quantifiable HBVDNA and HBsAg results prior to dosing at visit 2. Following the last IV administration of HBIG, have a baseline serum antiHBs level of &gt;150 IU/ML prior to dosing at visit 2. Exclusion Criteria Positive HCV or HIV test results. Unexplained elevated liver function tests. Serum creatinine level &gt;2.0 times the upper limit of normal. life expectancy &lt;6 months. liver transplantation with ongoing acute rejection episode. Donor liver that was from a hepatitis Bor C positive donor. Underwent a liver transplant &lt;12 months prior to visit 1. Know history of cancer, suspected cancer, or cancer therapy within 12 months. History of autoimmune disease. History/current evidence of coagulation disorder, severe cardiac disease, unhealed gastric or duodenal ulcer, or other significant disease. Evidence of any other unresolved infection and any unresolved opportunistic infection requiring treatment. Known immunoglobulin A deficiency. History of use of immunosupressive or immunomodulatory drug within 3 month prior to visit 1. (except low dose glucocorticoid therapy, &lt;10 mg of prednisone or equivalent per day.) received and investigational drug 30 days prior to visit 1. use of plasma preparations or other immunoglobulins during the study. Know intolerance to proteins of human origin, immunoglobulin, or comparable products. Evidence of alcohol and/or drug abuse within 6 month of visit 2 or inability/unwillingness to abstain from alcohol for the duration of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Chronic hepatitis B liver disease</keyword>
</DOC>